Medistim ASA (OSL:MEDI)
Norway · Delayed Price · Currency is NOK | Market Cap | 5.49B +24.6% |
| Revenue (ttm) | 795.98M +19.1% |
| Net Income | 178.39M +25.3% |
| EPS | n/a |
| Shares Out | 18.29M |
| PE Ratio | 30.76 |
| Forward PE | 27.49 |
| Dividend | 8.00 (2.67%) |
| Ex-Dividend Date | Oct 27, 2026 |
| Volume | 89,951 |
| Open | 302.00 |
| Previous Close | 281.00 |
| Day's Range | 300.00 - 315.00 |
| 52-Week Range | 186.50 - 315.00 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 342.50 (+14.17%) |
| Earnings Date | Oct 23, 2026 |
About Medistim ASA
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Asia, Europe, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplan... [Read more]
Financial Performance
In 2025, Medistim ASA's revenue was 699.77 million, an increase of 24.38% compared to the previous year's 562.60 million. Earnings were 159.21 million, an increase of 53.33%.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for MEDI stock is "Strong Buy." The 12-month stock price target is kr 342.50, which is an increase of 14.17% from the latest price.
News
Medistim ASA Earnings Call Transcript: Q2 2026
Record sales and EBIT were achieved in Q2 and H1 2026, driven by strong growth in own products and all regions, especially the Americas. Margins remained high, and the outlook was upgraded, with new product launches and market expansion expected to sustain growth.
Medistim ASA Quarterly report: Q2 2026
Medistim ASA has published its Q2 2026 quarterly earnings report on August 21, 2026.
Medistim ASA Slides: Q2 2026
Medistim ASA has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 21, 2026.
Medistim ASA Earnings Call Transcript: Q1 2026
Record quarterly revenue exceeded NOK 200 million, driven by strong own product sales and robust growth in all regions, especially Asia Pacific. EBIT margin remained strong despite U.S. tariffs and higher one-off expenses, with solid cash and equity positions maintained.
Medistim ASA Slides: Q1 2026
Medistim ASA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Medistim ASA Quarterly report: Q1 2026
Medistim ASA has published its Q1 2026 quarterly earnings report on May 7, 2026.
Medistim ASA Earnings Call Transcript: Q4 2025
Record sales and profit in 2025, with strong growth in Americas and imaging products. U.S. tariffs offset by price increases, and a direct office opened in Japan to drive further expansion. Dividend of NOK 8 per share proposed.
Medistim ASA Quarterly report: Q4 2025
Medistim ASA has published its Q4 2025 quarterly earnings report on February 27, 2026.
Medistim ASA Slides: Q4 2025
Medistim ASA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 27, 2026.
Medistim ASA Annual report: Q4 2025
Medistim ASA has published its Q4 2025 annual report on February 27, 2026.
Medistim ASA Earnings Call Transcript: Q3 2025
Record Q3 and year-to-date results with strong revenue and profit growth, led by Americas and Asia-Pacific. Imaging and cardiac products showed robust performance, while EMEA lagged due to high market penetration. Outlook remains positive, with focus on U.S., China, and vascular segment expansion.
Medistim ASA Quarterly report: Q3 2025
Medistim ASA has published its Q3 2025 quarterly earnings report on October 24, 2025.
Medistim ASA Slides: Q3 2025
Medistim ASA has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 24, 2025.